We invite you to read the scientific article about the Phase I clinical trial of Angipur, co-authored by Vasiliy Kazey, CEO of Exacte Labs. The scientific publication was published in the journal «Cardiovascular Therapy and Prevention».
Results of a clinical study on safety, pharmacokinetics and pharmacodynamics of an original antiplatelet drug from the group of glycoproteins IIb/IIIa-receptor inhibitors in healthy volunteers
Fitilyov S.B., Glukhov Yu.F., Lukyanov S.V., Vozzhaev A.V., Shkrebneva I.I., Kazey V.I., Bondareva I.B.
The full text of the publication can be found here.